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Background: Onset of Henoch-Schönlein purpura (HSP) in middle age is uncommon, and adults with renal or
gastrointestinal involvement present with more severe disease than do similar pediatric patients.
Case presentation: We present the case of a 69-year-old male with HSP who, after treatment with steroids,
cyclophosphamide, and continuous intravenous prostaglandin E1 (PGE1), died as a result of severe gastrointestinal
involvement with non-occlusive mesenteric ischemia (NOMI). Vascular narrowing associated with the NOMI
improved after catheter injection of PGE1 and prednisolone, but the patient died of bleeding from an exposed
small vessel. At autopsy there was no active vasculitis in the jejunal submucosa.
Conclusion: Treatment with PGE1 and prednisolone might improve small-vessel vasculitis associated with NOMI.
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Henoch-Schönlein purpura (HSP) is characterized by a
leukocytoclastic vasculitis involving the small vessels,
with deposition of immune complexes that contain IgA
[1,2]. Clinical signs include purpura, arthralgia, glome-
rulonephritis, and gastrointestinal involvement [3]. HSP
occurs primarily in children [4]. It is uncommon in
people over the age of 40, and little is known about its
natural history in this population [5]. The prognosis for
patients with childhood-onset HSP is good. However, the
clinical presentation of HSP in adults is severe and the
clinical outcome relatively poor [6]. In particular, deaths
have been reported in cases of adult HSP with severe
gastrointestinal involvement [7,8].
Non-occlusive mesenteric ischemia (NOMI) is defined as
acute mesenteric ischemia through hypoperfusion caused
by ongoing splanchnic vasoconstriction, without demon-
strable occlusion of the mesenteric vasculature [9]. NOMI
is a life-threatening vascular emergency that requires early
diagnosis and intervention to adequately restore mesenteric
blood flow and prevent bowel necrosis and patient death.* Correspondence: n-tsurikisawa@sagamihara-hosp.gr.jp
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reproduction in any medium, provided the orRisk factors for NOMI include hypovolemia, hypotension,
low cardiac output status, renal or hepatic disease, cardiac
surgery, and administration of α-adrenergic agonists,
digoxin, or β-receptor blocking agents [9]. There are
no published reports of NOMI associated with HSP.
We present a fatal case of HSP in an adult patient who
had severe gastrointestinal involvement with NOMI. After
treatment with steroids, cyclophosphamide, intravenous
steroids, prostaglandin E1 (PGE1), and continuous intra-
venous papaverine hydrochloride, the ischemic change
caused by small-vessel vasculitis of the small intestine
improved. Unfortunately, the patient had a poor prognosis
owing to bleeding from an exposed small vessel, although
at autopsy he had no apparent active vasculitis in the
jejunal submucosa.
Case presentation
A 69-year-old Japanese male presented with a history of
bronchial asthma from age 61 and hypertension from age
50. He had been treated with inhaled glucocorticosteroids,
long-acting inhaled β2-agonists, leukotriene modifiers,
methylxanthines, and antihypertensives. He was an ex-
smoker with a Brinkman Index of 1200. He had noticed
purpura appearing in both lower extremities without any
preceding infection, including upper respiratory tract infec-
tion. He then developed, without fever, edema in bothl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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after the patient had first noticed symptoms, the purpura
gradually improved. However, he began suffering from
abdominal pain, diarrhea, edema of the upper extremities,
and oliguria.
On admission, the patient had a body temperature of
36.9°C, a pulse of 109/min with sinus rhythm, and blood
pressure of 133/78 mm Hg. Physical examination revealed
pretibial pitting edema and diffuse small palpable purpuras
on both lower extremities (Figure 1A, B) and on the lower
abdomen. The patient’s heart and lung sounds were
normal. His abdomen was slightly distended, but neither
muscular guarding nor tenderness was detected. On
auscultation, the bowel was hypoactive. There was no
hepatosplenomegaly or existing masses. A neurological
examination revealed no abnormalities. An electrocardio-
gram and X-rays of the chest and abdomen were essentially
normal. Computed tomography of the patient’s abdomen
demonstrated diffuse thickening of the bowel wall, with
target signs in the small intestine and ascites (Figure 2A).
The white blood cell count was 14,260/μL, hemoglobin
was 16.4 g/dL, and C-reactive protein was 22.36 mg/dL.
There was microscopic hematuria and proteinuria. A skin
biopsy taken from the right leg showed purpura.
On the second hospital day, abdominal pain and melena
in our patient appeared after the purpura improved and
before treatment with steroids or immunosuppressants.
Upper and lower gastrointestinal endoscopic investigationFigure 1 Purpura. (A) Diffuse small palpable purpura on the lower extremon day 4 revealed irregular ulcerations in the stomach and
the duodenum and erythema in the sigmoid colon. The
ascending colon and cecum were not observable, owing to
the presence of a stricture caused by severe edema of the
mucosa. However, there were patchy areas of erythema in
the sigmoid colon (Figure 3A) and rectum (Figure 3B).
Cutaneous leukocytoclastic vasculitis was confirmed by
skin biopsy. The patient was diagnosed with HSP on the
basis of American College of Rheumatology criteria [10].
Computed tomography of the abdomen performed on day
9 showed severe edematous and dilatational changes in
the small intestine and ascites before treatment with
steroids and cyclophosphamide (Figure 2B).
After intravenous treatment with Factor XIII concentrate
(20 mL/day for 3 consecutive days) and prednisolone
sodium succinate (40 mg/day for 13 consecutive days; see
Figure 4 for dosage schedules of all drugs), the skin lesions
and abdominal pain disappeared completely. However,
gastrointestinal hemorrhage and mild proteinuria remained
(Figure 4) and did not improve upon treatment with intra-
venous methylprednisolone (pulse dose of 1000 mg/day for
3 consecutive days) and intravenous cyclophosphamide
(800 mg on 1 day). Twenty-nine days after treatment began,
the ascites remained, and there were severe edematous
changes in the small intestine (Figure 2C). Colonoscopy
confirmed frank bleeding from the ascending sigmoid colon
(Figure 3C, Dc, d). Neither bleeding points nor vascular oc-
clusion was detected by mesenteric angiography. However,ities. (B) Magnified view.
Figure 2 Computed tomography of the abdomen. (A) Computed tomography of the abdomen performed on admission, showing diffuse
thickening of the bowel wall with target signs in the small intestine and ascites (arrow). (B) Computed tomography of the abdomen performed
on day 9, showing severe edematous and dilatational changes in the small intestine and ascites (arrow) before treatment with steroids and
cyclophosphamide. (C) Computed tomography of the abdomen performed on day 29 before treatment, showing ascites (arrows) that remained
after treatment with steroids and cyclophosphamide. However, the severe edematous changes in the small intestine were slightly improved
relative to day 9.
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major branches of the superior mesenteric artery and
absence of blood flow, indicative of NOMI (Figure 5Aa).
On day 30, blood flow in the superior mesenteric artery
increased and vascular narrowing improved after catheter
injection of 10 μg of PGE1 and 20 mg of predniso-
lone sodium succinate into the artery (Figure 5B).
After the intervention, proteinuria decreased. How-
ever, subsequent continuous intra-arterial infusion ofFigure 3 Colonoscopy findings. Colonoscopy images showing patchy er
treatment began. (C, D) Colonoscopy images showing fresh bleeding in th
and cyclophosphamide.papaverine hydrochloride (100 mg/h) did not improve the
patient’s gastrointestinal hemorrhaging, and renal function
deteriorated. He died on the 33rd hospital day.
Examination at autopsy showed widely distributed
jejunoileal ulcers of irregular form. Histopathologic
examination of the submucosa of the jejunum revealed an
exposed small vessel (Figure 6A), as well as obliteration of
small vessels and ruptured elastic laminae in the tunica
externa of those vessels (Figure 6B). There was also anythema in the sigmoid colon (A) and rectum (B) on day 4, before
e ascending sigmoid colon on day 29, after treatment with steroids
Figure 4 Treatment and clinical course. Top panel, doses and schedules of drug therapies. Middle panels, clinical findings. Abdominal pain and
melena appeared after improvement of purpura and before treatment with steroid and immunosuppressants. The patient’s melena and
proteinuria did not improve after treatment with steroids, cyclophosphamide, infusion of RCC-LR (red cell concentrates – leukocytes reduced),
and intravenous PGE1 (prostaglandin E1). Bottom panels, laboratory findings. Cre, creatinine; CRP, C-reactive protein; Hb, hemoglobin.
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jejunum but no regeneration of the epithelium. There was
no evidence of active vasculitis or thrombosis in the tunica
media of the superior mesenteric artery (Figure 6C),
although there were edematous changes (Figure 6D). TheseFigure 5 Supramesenteric artery angiography. (A) Mesenteric angiogra
presence of narrowing and irregularity of major branches of the superior m
blood flow and reduced vascular narrowing after catheter injection of 10 μ
superior mesenteric artery.findings suggest that severe vasospasm due to small-vessel
vasculitis before treatment with PGE1 plus steroid had
caused wide ischemic changes and delayed regeneration of
the epithelium in the submucosa of the small intestine. We
considered that the primary cause of death was bleedingm showing absence of bleeding points and vascular occlusion, but
esenteric artery. (B) Mesenteric angiogram taken on day 30, showing
g of PGE1 and 20 mg of prednisolone sodium succinate into the
Figure 6 Autopsy findings. Biopsy samples were fixed and stained with hematoxylin and eosin. Histopathology of the jejunal submucosa shows
(A) an exposed small vessel (arrow) (x40) and (B) exposed vessel and ruptured elastic laminae in the tunica externa of that vessel (x100).
Histopathology of the tunica media of the superior mesenteric artery shows (C) no active vasculitis or thrombosis at autopsy (x40), but (D)
edematous change (x200).
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vasculitis in the jejunal submucosa. Other findings
were typical of HSP and included mesangial proliferative
glomerulonephritis with crescent formation.
Discussion
Although HSP is typically a disease of children, adult cases
can occur and present as more severe disease. Serious
complications related to gastrointestinal involvement in-
clude intussusception, infarction, and perforation [7,11,12].
HSP patients who are older than 60 years at onset and
who have renal or gastrointestinal involvement have a poor
prognosis [5-8,13]. Some patients with gastrointestinal in-
volvement die despite treatment with steroids and immu-
nosuppressants [8,13]. Among adult patients with HSP,
24.1% have initial onset with gastrointestinal involvement
before the cutaneous rash [11], and those manifestations
may be helpful for early diagnosis and for selecting
appropriate management strategies [12].
Few reports of NOMI associated with small-vessel vascu-
litis have been published. There has been one case report
of vasculitic lesions that resulted in dialysis-related
hypotension and NOMI, but this was associated with giant
cell arteritis [14]. NOMI in our patient might have been
caused by active vasculitis, but it appeared not to have
been caused by hypotension or hypovolemia, and thepatient did not receive drugs such as α-adrenergic agonists,
digoxin, or β-receptor blocking agents, which are known
to precipitate this condition [9]. NOMI has a high morta-
lity rate, and early diagnosis and treatment are important
for improving survival [15]. Early treatment of NOMI
patients with continuous intravenous PGE1 increases
survival rates [15,16]. Abdominal pain and melena in our
patient appeared after the purpura improved and before
treatment with steroids or immunosuppressants. The
patient’s melena and renal dysfunction did not improve
after treatment with steroids, cyclophosphamide, and intra-
venous PGE1 and steroids. At autopsy, an exposed small
vessel was identified, but there was no evidence of active
vasculitis in the submucosa of the jejunum. We suspect
that the treatment for NOMI improved vasodilatation in
the submucosa of the small intestine, thus improving the
distribution of the locally injected steroid or the ongoing
systemic steroid and immunosupressant to the submucosa
of the jejunum. We considered that exposure of the small
vessel, possibly as a result of the remodeling process in the
submucosa, was the cause of death.
Conclusion
Treatment of NOMI results in vasodilatation, thus
resulting in more effective treatment of the active
small-vessel vasculitis associated with HSP.
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